In first instance we have decided to assess whether the ErbB3 autocrine survival loop induced by treatment with BRAF and/or MEK inhibitors is a general phenomenon using a larger panel of melanoma cell lines and whether in vitro treatment with anti-ErbB3 antibodies is capable of suppressing the establishment of resistance to BRAFi. This evidence concerns the gene ERBB3 and melanoma.